The board of directors of SSY Group Limited announced that the Group's Cinacalcet Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Cinacalcet is mainly used for the treatment of secondary hyperparathyroidism, primary hyperparathyroidism and parathyroid carcinoma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 HKD | +0.93% | +0.70% | -12.15% |
07-17 | SSY Group Obtains Registration Go-Ahead for 2 Drugs from Chinese Regulator | MT |
07-16 | Chinese Regulator OKs SSY Group's Betahistine Mesilate Tablets for Drug Production, Registration | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.15% | 1.64B | |
+55.35% | 815B | |
+32.40% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.25% | 247B | |
+14.52% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Provides Update on Product Development